Statement: A significantly higher proportion of patients in the secondary trial suffured from infection compared to the primary trial.
Primary_evidence: Adverse Events 1:   Total: 1/41 (2.44%)   Infection  1/41 (2.44%)   Creatinine  1/41 (2.44%)   Hypokalemia  1/41 (2.44%)   Bicarbonate  1/41 (2.44%)   SGOT  1/41 (2.44%)   Alkaline Phosphatase value  1/41 (2.44%)   Hyperbilirubineamia  1/41 (2.44%)   Hypoalbuminemia  1/41 (2.44%)   Leukocytes  1/41 (2.44%)   Hemoglobin  1/41 (2.44%)   Neutrophils  1/41 (2.44%)   INR  1/41 (2.44%)   PTT  1/41 (2.44%) Adverse Events 2:
Secondary_evidence: Adverse Events 1:   Total: 14/81 (17.28%)   Neutropenia1/81 (1.23%)   Cataract1/81 (1.23%)   Ascites1/81 (1.23%)   Gastritis Hemorrhagic1/81 (1.23%)   Nausea1/81 (1.23%)   Stomatitis2/81 (2.47%)   Malaise1/81 (1.23%)   Oedema1/81 (1.23%)   Pain1/81 (1.23%)   Pyrexia1/81 (1.23%)   Infection2/81 (2.47%)   Upper Limb Fracture1/81 (1.23%)   Dehydration1/81 (1.23%)   Hypercalcemia1/81 (1.23%)